Go Deep
RPG Life Sciences Limited
RPG Life Sciences Limited Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 21,674 | 37.6 | 7.43 | 0.03 | 2,719.20 |
| Oct 2026 | 20,769 | 37.6 | 7.43 | 0.03 | 2,719.20 |
RPG Life Sciences Limited Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Jun 2025 |
|---|---|---|---|---|
| Revenue | 1,956,900,000.0 | 1,768,900,000.0 | 1,800,300,000.0 | 1,689,200,000.0 |
| Net Profit | 307,600,000.0 | 299,000,000.0 | 221,300,000.0 | 262,900,000.0 |
| EPS | 18.6 | 18.1 | 13.4 | 15.9 |
RPG Life Sciences Limited Revenue & Profit: Last 4 Years
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Revenue | 7,020,000,000.0 | 6,475,400,000.0 | 5,774,800,000.0 | 5,090,800,000.0 |
| Net Profit | 1,151,700,000.0 | 1,832,400,000.0 | 876,600,000.0 | 676,400,000.0 |
| EPS | 69.6 | 110.8 | 53.0 | 40.9 |
RPG Life Sciences Limited Balance Sheet
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Total Assets | 7,931,600,000.0 | 6,578,100,000.0 | 5,128,700,000.0 | 4,193,500,000.0 | — |
| Total Liabilities | 1,878,100,000.0 | 1,272,800,000.0 | 1,380,200,000.0 | 1,117,500,000.0 | — |
| Total Equity | 6,053,500,000.0 | 5,305,300,000.0 | 3,748,500,000.0 | 3,076,000,000.0 | — |
Owes vs Owns
RPG Life Sciences Limited owed ₹0.24 for every ₹1 it owned in Mar 2026, down from ₹0.27 in Mar 2023.
| Period | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Owes vs Owns | 0.24× | 0.19× | 0.27× | 0.27× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
RPG Life Sciences Limited Assets & Liabilities Breakdown (₹ Cr)
What it owns — Mar 2026
Cash & short-term investments 34.6%Receivables 14.7%Inventory 15.6%Fixed assets (tangible) 26.7%Intangible assets 1.0%Other assets 7.2%
How it's funded — Mar 2026
Short-term debt 0.8%Long-term debt 1.7%Payables 12.3%Other liabilities 8.9%Shareholders' equity 76.3%
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 274.4 | 264.6 | 125.9 | 114.8 |
| Receivables | 116.7 | 86.8 | 49.1 | 37.4 |
| Inventory | 123.8 | 93.0 | 101.0 | 95.0 |
| Fixed assets (tangible) | 211.7 | 165.1 | 181.8 | 116.3 |
| Intangible assets | 8.1 | 22.8 | 28.0 | 33.4 |
| Long-term investments | 1.0 | 1.0 | 1.0 | 0.0 |
| Other assets | 57.4 | 24.6 | 26.0 | 22.4 |
| Liabilities & equity | ||||
| Short-term debt | 6.7 | 0.0 | 0.0 | 0.0 |
| Long-term debt | 13.3 | 0.0 | 0.0 | 0.0 |
| Payables | 97.2 | 79.4 | 71.0 | 64.7 |
| Other liabilities | 70.6 | 47.9 | 67.0 | 47.0 |
| Shareholders' equity | 605.4 | 530.5 | 374.9 | 307.6 |
| Net tangible assets | 597.2 | 507.8 | 346.8 | 274.2 |
RPG Life Sciences Limited Cash Flow
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Operating Activities | 565,000,000.0 | 778,600,000.0 | 943,600,000.0 | 908,200,000.0 | — |
| Investing Activities | 858,400,000.0 | -418,000,000.0 | -791,500,000.0 | -1,058,100,000.0 | — |
| Financing Activities | -205,800,000.0 | -270,800,000.0 | -203,100,000.0 | -171,200,000.0 | — |